Nuformix PLC (LSX:A141LG) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Rights offering of open Offer Shares (ordinary shares) Announced: about £228,081 · GBX 0.2 a share · CMC Markets UK Plc Dealers: CMC Markets UK Plc Use of proceeds: Assess NXP002's inhaled therapeutic window, support partnering and out-licensing talks, maintain key IP, and working capital | Oct 28, 2025 | US$302,850 |
| Private placement of new ordinary shares Update: £210,000 · GBX 0.07 a share · CMC Markets UK Plc Dealers: CMC Markets UK Plc | May 23, 2025 | US$283,766 |
| Warrant exercise of new ordinary shares Announced: £13,200 · GBX 0.05 a share | Apr 14, 2025 | US$17,392 |
| Private placement of new ordinary shares Announced: £168,750 · GBX 0.0675 a share · CMC Markets UK Plc, trading as CMC CapX Dealers: CMC Markets UK Plc, trading as CMC CapX (lead) Use of proceeds: Progress partnering discussions for NXP002 inhaled IPF/PPF programme and general corporate purposes | Jan 30, 2025 | US$210,182 |